Key result
Recent data suggests the existence of a subclinical form of primary aldosteronism and highlights progress in understanding its molecular basis, which may offer new therapeutic targets.
Why the study?
Primary aldosteronism is a common cause of secondary hypertension associated with elevated cardiovascular risk, prompting a thorough presentation and critical discussion of novel, clinically meaningful insights.
This narrative review highlights novel insights into primary aldosteronism, including the potential existence of a subclinical form and progress in understanding its molecular basis for future therapeutic targets.
Alerts clinicians to excess CV risk in primary aldosteronism; extends literature but leaves open prospective outcome trials.
BACKGROUND: Primary aldosteronism is one of the most common causes of secondary hypertension. Patients with this endocrine syndrome are at increased cardiovascular risk, higher than hypertensive individuals with equal blood pressure levels. OBJECTIVES: The study aimed to thoroughly present and critically discuss the novel insights into the field of primary aldosteronism, focusing on the clinically meaningful aspects. METHOD: We meticulously evaluated existing data in the field of primary aldosteronism in order to summarize future perspectives in this narrative review. RESULTS: Novel data suggests that a subclinical form of primary aldosteronism might exist. Interesting findings might simplify the diagnostic procedure of the disease, especially for the localization of primary aldosteronism. The most promising progress has been noted in the field of the molecular basis of the disease, suggesting new potential therapeutic targets. CONCLUSION: Several significant aspects are at early stages of evaluation. Future research is essential to investigate these well-promising perspectives.
No takes yet. Share an insight, caveat, or question.
Stavropoulos et al. (2019) conducted a review in Primary aldosteronism. Recent data suggests the existence of a subclinical form of primary aldosteronism and highlights progress in understanding its molecular basis, which may offer new therapeutic targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: